🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07677696
Recruiting Observational

Evaluating Midline Catheters in Clinical Practice

NCT07677696 · tracked via the Priya Life Science China tracker
Sponsor
Shandong Branden Med.Device Co.,Ltd
Phase
Observational
Started
2026-05-01
Last updated
2026-07-01

Condition(s) studied

Safety and Effectiveness of Midline CathetersVascular Access Devices

Investigational drug(s) / intervention(s)

Midline catheter placement

Midline catheter placement: Patients receive a midline catheter as part of their routine clinical care for intravenous therapy lasting 1 to 4 weeks

Study summary

The goal of this observational study is to learn about the safety and effectiveness of midline catheters in patients who receive midline catheter placement as part of their routine clinical care. The main question it aims to answer is:

Do midline catheters demonstrate acceptable safety and effectiveness when used in routine clinical practice?

Participants who receive a midline catheter as part of their regular medical care will have their clinical data collected from electronic medical records and patient questionnaires, and followed for outcomes related to catheter-related complications and functional performance.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * First-time midline catheter placement per physician order * Not enrolled in another clinical study * Willing and able to provide informed consent and comply with follow-up (unless consent waived by local ethics committee) Exclusion Criteria: * Deemed unsuitable by investigator (e.g., poor compliance or inability to communicate clearly) * Refusal of informed consent by patient or family member

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zibo Central Hospital Zibo China Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07677696 on ClinicalTrials.gov ↗ ← All trials in China